These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8041892)

  • 41. Deterministic models for the eradication of poliomyelitis: vaccination with the inactivated (IPV) and attenuated (OPV) polio virus vaccine.
    Eichner M; Hadeler KP
    Math Biosci; 1995 Jun; 127(2):149-66. PubMed ID: 7795316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Childhood immunizations: position on the enhanced inactivated poliovirus vaccine and live attenuated oral poliovirus vaccine dilemma.
    Willis E; Sherrod JL
    J Natl Med Assoc; 1997 Dec; 89(12):785-9. PubMed ID: 9433057
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Basic conditions for the eradication of poliomyelitis--indications for a common prescription.
    Swartz TA
    Public Health Rev; 1993-1994; 21(1-2):157-60. PubMed ID: 8041884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [End phase challenges of poliomyelitis eradication programme realization].
    Jarzabek Z
    Przegl Epidemiol; 2005; 59(1):59-68. PubMed ID: 16013411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Introduction of inactivated polio vaccine (IPV) into the routine immunization schedule of South Africa.
    Schoub BD
    Vaccine; 2012 Sep; 30 Suppl 3():C35-7. PubMed ID: 22939019
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [VACCINE-ASSOCIATED PARALYTIC POLIOMYELITIS IN RUSSIAN FEDERATION DURING THE PERIOD OF CHANGES IN VACCINATION SCHEDULE (2006-2013 yy.)].
    Ivanova OE; Eremeeva TP; Morozova NS; Shakaryan AK; Gmyl AP; Yakovenko ML; Korotkova EA; Chernjavskaja OP; Baykova OY; Silenova OV; Krasota AY; Krasnoproshina LI; Mustafina AN; Kozlovskaja LI
    Vopr Virusol; 2016; 61(1):9-15. PubMed ID: 27145594
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Circulating vaccine-derived poliovirus type 2 outbreak in Democratic Republic of Congo 2011-2012].
    Bazira L; Coulibaly T; Mayenga M; Ncharre C; Yogolelo R; Mbule A; Moudzeo H; Lwamba P; Mulumba AW; Cabore J
    Bull Soc Pathol Exot; 2015 Oct; 108(4):235-41. PubMed ID: 26288132
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Update on vaccine-derived polioviruses--worldwide, April 2011-June 2012.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Sep; 61():741-6. PubMed ID: 22992572
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modeling the dynamics of oral poliovirus vaccine cessation.
    Thompson KM; Duintjer Tebbens RJ
    J Infect Dis; 2014 Nov; 210 Suppl 1():S475-84. PubMed ID: 25316870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?
    Khan MM
    Vaccine; 2008 Apr; 26(16):2034-40. PubMed ID: 18339460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Universal use of inactivated poliovirus vaccine--the needs and challenges].
    Shimizu H; Takeda N
    Nihon Rinsho; 2008 Oct; 66(10):1950-5. PubMed ID: 18939495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Israel in the elimination phase of poliomyelitis--achievements and remaining problems.
    Swartz TA; Handsher R
    Public Health Rev; 1993-1994; 21(1-2):99-106. PubMed ID: 8041893
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Poliomyelitis--why we must continue to vaccinate!].
    Windorfer A; Beyrer K
    MMW Fortschr Med; 2005 Feb; 147(8):36, 38, 40. PubMed ID: 18437859
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vaccination against poliomyelitis in economically underdeveloped countries.
    Sabin AB
    Bull World Health Organ; 1980; 58(1):141-57. PubMed ID: 6966544
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Polio eradication: the OPV paradox.
    Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
    Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Progress toward global eradication of poliomyelitis, 1995.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1996 Jul; 45(26):565-8. PubMed ID: 9132575
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paralytic poliomyelitis--United States, 1980-1994.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Jan; 46(4):79-83. PubMed ID: 9048844
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule.
    Miller MA; Sutter RW; Strebel PM; Hadler SC
    JAMA; 1996 Sep; 276(12):967-71. PubMed ID: 8805731
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication.
    Más Lago P; Cáceres VM; Galindo MA; Gary HE; Valcarcel M; Barrios J; Sarmiento L; Avalos I; Bravo JA; Palomera R; Bello M; Sutter RW; Pallansch MA; de Quadros CA
    Int J Epidemiol; 2001 Oct; 30(5):1029-34. PubMed ID: 11689516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of the administration of oral poliovirus vaccine on infantile diarrhoea mortality.
    Contreras G
    Vaccine; 1989 Jun; 7(3):211-2. PubMed ID: 2781855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.